This study is currently not recruiting participants.

A Pilot Study of Sutent?/Sunitinib (SU11248) an Oral Multi-Targeted Tyrosine Kinase Inhibitor in Subjects With NF-1 Plexiform Neurofibromas

Investigating Treatment for Plexiform Neurofibromas in NF1 Patients

Not Recruiting
7 years - 65 years
All
Phase N/A

Brief description of study.

The purpose of this study is to determine the response rate of NF1 patients with plexiform neurofibromas treated with Sunitinib therapy using MRI scans.

Detailed description of study

The purpose of this study is to determine the response rate of NF1 patients with plexiform neurofibromas treated with Sunitinib therapy using MRI scans.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: NF-1 Plexiform Neurofibromas
  • Age: 7 years - 65 years
  • Gender: All

This study investigates the treatment of plexiform neurofibromas in patients with Neurofibromatosis Type 1 (NF1). Plexiform neurofibromas are a type of tumor that grows along nerves and can cause significant health issues. The purpose of this study is to see how these tumors respond to treatment with an investigational medication.

Participants will undergo MRI scans to monitor the response of their tumors to the investigational treatment. MRI, or Magnetic Resonance Imaging, is a medical imaging technique used to visualize internal structures of the body in detail.

  • Who can participate: Participants must have Neurofibromatosis Type 1 with plexiform neurofibromas. No specific age criteria.
  • Study details: Participants will receive the investigational medication Sunitinib. They will also undergo MRI scans to assess the treatment's effects on their tumors.
Updated on 19 Feb 2024. Study ID: 1106005788

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team